logo
logo
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

NASDAQ•FATE
CEO: Dr. Bahram Valamehr M.B.A., Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2013-10-01
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
連絡先情報
12278 Scripps Summit Drive, San Diego, CA, 92131, United States
858-875-1800
www.fatetherapeutics.com
時価総額
$125.73M
PER (TTM)
-0.8
34.6
配当利回り
--
52週高値
$1.94
52週安値
$0.66
52週レンジ
34%
順位62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$1.74M-43.36%
直近4四半期の推移

EPS

-$0.27-32.50%
直近4四半期の推移

フリーCF

-$26.58M-11.15%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Nine-month net loss narrowed to $103.9 M from $134.1 M in 2024, driven by lower operating expenses across R&D and G&A.
Operating Cash Burn Improved Cash used in operating activities decreased to $82.8 M for nine months, reflecting better cost management post-restructuring efforts.
R&D Spending Lowered Research and development expenses totaled $82.4 M for nine months, down $19.0 M compared to the prior year period.
CIRM Funding Received Received $3.8 M from FT836 CIRM award and $5.1 M total from FT819 award, recorded as liabilities on balance sheet.

リスク要因

Substantial Future Capital Required Anticipates continued operating losses requiring substantial additional funding to complete development and seek regulatory approval.
Novel Technology Uncertainty iPSC platform and gene-editing technologies face high technological uncertainty; development success is not assured.
Manufacturing Scale-Up Risks Complex manufacturing processes for cell therapies risk cost overruns, quality control issues, and potential regulatory delays.
Ongoing Legal Proceedings Currently defending against securities class action and derivative litigation, which could divert resources and incur costs.

見通し

Focus on Clinical Development Plan to significantly invest in current R&D, including clinical trials, GMP production, and technology transfer activities.
Ono Funding Secured Committed funding from Ono collaboration continues through June 2026, supporting research and preclinical development efforts.
Extended Cash Runway August 2025 restructuring aims to reduce operating expenses and extend cash runway through the end of 2027.
Navigating Regulatory Landscape Will continue engaging regulatory authorities for development pathways, anticipating potential changes in requirements.

同業比較

売上高 (TTM)

Alector, Inc.ALEC
$69.05M
+12.3%
Innate Pharma S.A.IPHA
$36.93M
-61.2%
Tonix Pharmaceuticals Holding Corp.TNXP
$10.30M
-8.8%

粗利益率 (最新四半期)

Alector, Inc.ALEC
100.0%
+0.0pp
Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Fate Therapeutics, Inc.FATE
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PEPG$378.80M-1.9-84.1%9.2%
FBRX$369.29M-10.1-75.6%0.0%
ACHV$232.10M-2.9-196.7%19.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-2.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月4日
|
EPS:-$0.27
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $1.74M-43.4%
    |
    EPS: $-0.27-32.5%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月12日|
    売上高: $1.91M-71.8%
    |
    EPS: $-0.29-12.1%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月13日|
    売上高: $1.63M-15.4%
    |
    EPS: $-0.32-31.9%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月5日|
    売上高: $13.63M-78.5%
    |
    EPS: $-1.64+0.0%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $3.07M+58.1%
    |
    EPS: $-0.40-13.0%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月13日|
    売上高: $6.77M+625.8%
    |
    EPS: $-0.33-38.9%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $1.93M-96.7%
    |
    EPS: $-0.47+402.7%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月26日|
    売上高: $63.53M-34.0%
    |
    EPS: $-1.64+43.6%
    予想を下回る